CompletedPhase 2NCT00053196
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Studying Acute myeloid leukemia with 11q23 abnormalities
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Asad Bashey, MD, PhD, Ph.DUniversity of California, San Diego
- Intervention
- anti-thymocyte globulin(biological)
- Enrollment
- 82 enrolled
- Eligibility
- 69 years · All sexes
- Timeline
- 2002 – 2010
Study locations (12)
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- St. Francis Hospital, Wilmington, Delaware, United States
- Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States
- Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States
- Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees Township, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
- Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00053196 on ClinicalTrials.govOther trials for Acute myeloid leukemia with 11q23 abnormalities
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington
- RECRUITINGPHASE3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
See all trials for Acute myeloid leukemia with 11q23 abnormalities →